Global Autologous Cell Therapy Market 2017-2021

  • ID: 4307467
  • Report
  • Region: Global
  • 92 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AbbVie
  • BIOTIME
  • Citospin
  • Histocell
  • Osiris Therapeutics
  • Shire
  • MORE
About Autologous Cell Therapy

Autologous cell therapy belongs to the field of regenerative medicine and is based on biologic cell-based therapies to cure various diseases, including those of oncology, neurology, and dermatology, to name a few. Autologous cell therapy is one of the fastest growing segments of regenerative medicine and hence, is attracting significant research funds from various quarters.

The analysts forecast the global autologous cell therapy market to grow at a CAGR of 23.39% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global autologous cell therapy market for 2017-2021. To calculate the market size, the report considers the sales of autologous stem cell as well non-stem cell products.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Autologous Cell Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors
- Brainstorm Cell Therapeutics
- Holostem Advanced Therapies
- Osiris Therapeutics
- Valeant
- Vericel Corporation
Other prominent vendors
- AbbVie
- American CryoStem
- AM-Pharma
- Anterogen
- apceth Biopharma
- Astellas Pharma
- Athersys
- Baxter International
- Beike Biotechnology
- BIOTIME
- bluebird bio
- Bristol-Myers Squibb
- Brainxell
- Caladrius Biosciences
- Cellular Biomedicine Group
- Cellular Dynamics International (a subsidiary of Fujifilm)
- Cesca Therapeutics
- CHA Biotech
- Chugai Pharmaceutical
- Citospin
- Corestem
- Cytori Therapeutics
- Daiichi Sankyo
- Fujifilm
- Gamida Cell
- Global Stem Cells Group
- Grupo Ferrer Internacional
- GlaxoSmithKline
- Hemostemix
- Histocell
- International Stem Cell
- Ivy Institute of Stem Cells
- Japan Regenerative Medicine
- Kangstem Biotech
- Kiadis Pharma
- Laboratorios Salvat
- MEDIPOST
- Mesoblast
- Nuo Therapeutics
- Opsis Therapeutics
- Pharmicell
- Pluristem Therapeutics
- Promethera Biosciences
- Q Therapeutics
- ReNeuron
- RHEACELL
- Salus Medical Solutions
- Sangamo Therapeutics
- Shire
- Steminent Biotherapeutics
- Sumitomo Dainippon Pharma
- Taiwan Bio Therapeutics
- Takeda Pharmaceutical
- Teva Pharmaceutical Industries
- Thoratec Corporation
- TiGenix
- Translational Biosciences
- TWO CELLS
- U.S. Stem Cell
- ViaCyte
- VistaGen Therapeutics

Market drivers
- Increasing demand for effective drugs for cardiac and degenerative disorders
- For a full, detailed list, view the full report

Market challenges
- Critical ethical challenges with respect to stem cell research
- For a full, detailed list, view the full report

Market trends
- Private funding will fuel market growth
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key Market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are theKey vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • BIOTIME
  • Citospin
  • Histocell
  • Osiris Therapeutics
  • Shire
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Market outline
PART 05: Pipeline Landscape

PART 06: Market landscape
  • Market overview
  • Five forces analysis
PART 07: Market segmentation by application
  • Oncology
  • Musculoskeletal disorders
  • Dermatology
PART 08: Market Segmentation by therapy
  • Autologous stem cell therapy
  • Autologous cellular immunotherapies
PART 09: Geographical segmentation
  • Autologous cell therapy market in Americas
  • Autologous cell therapy market in EMEA
  • Autologous cell therapy market in APAC
PART 10: Decision framework

PART 11: Drivers and challenges
  • Market drivers
  • Market challenges
PART 12: Market trends
  • Private funding will fuel market growth
  • Development of stem cell therapies by new regions
  • Increasing focus on development of drugs for emerging applications
PART 13: Vendor landscape
  • Competitive scenario
PART 14: Key vendor analysis
  • Brainstorm Cell Therapeutics
  • Holostem Advanced Therapies
  • Osiris Therapeutics
  • Valeant
  • Vericel Corporation
  • Other prominent vendors
PART 15: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Ethical issues faced by various institutes at different phases of research
Exhibit 02: Key Pipeline landscape
Exhibit 03: Global autologous cell therapy market: Snapshot
Exhibit 04: Global autologous cell therapy market 2016-2021 ($ millions)
Exhibit 05: Global autologous cell therapy market: Opportunity analysis
Exhibit 06: Five forces analysis
Exhibit 07: Global autologous cell therapy market segmentation by application 2016
Exhibit 08: Overview of oncology segment in global autologous cell therapy market
Exhibit 09: Overview of musculoskeletal disorders segment in global autologous cell therapy market
Exhibit 10: Overview of dermatology segment in global autologous cell therapy market
Exhibit 11: Global autologous cell therapy market segmentation by therapy 2016
Exhibit 12: Global autologous stem cell therapy market 2016-2021 ($ millions)
Exhibit 13: Global autologous cellular immunotherapies therapy market 2016-2021 ($ millions)
Exhibit 14: Segmentation of global autologous cell therapy market based on geography 2016 and 2021
Exhibit 15: Global autologous cell therapy market revenue by geography 2016-2021 ($ millions)
Exhibit 16: Market scenario in Americas
Exhibit 17: Autologous cell therapy market in Americas 2016-2021 ($ millions)
Exhibit 18: Market scenario in EMEA
Exhibit 19: Autologous cell therapy market in EMEA 2016-2021 ($ millions)
Exhibit 20: Market scenarios in APAC
Exhibit 21: Autologous cell therapy market in APAC 2016-2021 ($ millions)
Exhibit 22: Competitive structure analysis of global stem cell therapy market 2016
Exhibit 23: Strategic success factors of companies in global autologous cell therapy market
Exhibit 24: Brainstorm Cell Therapeutics: Key highlights
Exhibit 25: Brainstorm Cell Therapeutics: Strength assessment
Exhibit 26: Brainstorm Cell Therapeutics: Strategy assessment
Exhibit 27: Brainstorm Cell Therapeutics: Opportunity assessment
Exhibit 28: Holostem Advanced Therapies: Key highlights
Exhibit 29: Holostem Advanced Therapies: Strength assessment
Exhibit 30: Holostem Advanced Therapies: Strategy assessment
Exhibit 31: Holostem Advanced Therapies: Opportunity assessment
Exhibit 32: Osiris Therapeutics: Key highlights
Exhibit 33: Osiris Therapeutics: Strength assessment
Exhibit 34: Osiris Therapeutics: Strategy assessment
Exhibit 35: Osiris Therapeutics: Opportunity assessment
Exhibit 36: Valeant: Key highlights
Exhibit 37: Valeant: Strength assessment
Exhibit 38: Valeant: Strategy assessment
Exhibit 39: Valeant: Opportunity assessment
Exhibit 40: Vericel Corporation: Key highlights
Exhibit 41: Vericel Corporation: Strength assessment
Exhibit 42: Vericel Corporation: Strategy assessment
Exhibit 43: Vericel Corporation: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie
  • BIOTIME
  • Citospin
  • Histocell
  • Osiris Therapeutics
  • Shire
  • MORE
New Report Released: – Global Autologous Cell Therapy Market 2017-2021

The author of the report recognizes the following companies as the key players in the global autologous cell therapy market: Brainstorm Cell Therapeutics, Holostem Advanced Therapies, Osiris Therapeutics, Valeant, and Vericel.

Other Prominent Vendors in the market are: AbbVie, American CryoStem, AM-Pharma, Anterogen, apceth Biopharma, Astellas Pharma, Athersys, Baxter International, Beike Biotechnology, BIOTIME, bluebird bio, Bristol-Myers Squibb, Brainxell, Caladrius Biosciences, Cellular Biomedicine, Cellular Dynamics International, Cesca Therapeutics, CHA Biotech, Chugai Pharmaceutical, Citospin, Corestem, Cytori Therapeutics, Daiichi Sankyo, Fujifilm, Gamida Cell, Global Stem Cells, Grupo Ferrer Internacional, GlaxoSmithKline, Hemostemix, Histocell, International Stem Cell, Ivy Institute of Stem Cells, Japan Regenerative Medicine, Kangstem Biotech, Kiadis Pharma, Laboratorios Salvat, MEDIPOST, Mesoblast, Nuo Therapeutics, Opsis Therapeutics, Pharmicell, Pluristem Therapeutics, Promethera Biosciences, Q Therapeutics, ReNeuron, RHEACELL, Salus Medical Solutions, Sangamo Therapeutics, Shire, Steminent Biotherapeutics, Sumitomo Dainippon Pharma, Taiwan Bio Therapeutics, Takeda Pharmaceutical, Teva Pharmaceutical Industries, Thoratec, TiGenix, Translational Biosciences, TWO CELLS, U.S. Stem Cell, ViaCyte, and VistaGen Therapeutics.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is private funding will fuel market growth. The increasing investments from private enterprises will likely change the market dynamics. Many vendors are investing in production or manufacturing facilities to improve their production or manufacturing expertise. They are also focusing on establishing new business units or companies to penetrate the market further.”

According to the report, one of the major drivers for this market is increasing demand for effective drugs for cardiac and degenerative disorders. There has been an increased demand for providing effective drugs for cardiac and degenerative disorders globally. Prior to the advent of autologous cell therapies, there was no effective drug to repair a damaged heart. The discovery of possible cardiac autologous cells opened new possibilities for repairing damaged cardiac tissue caused by acute myocardial infarction or coronary artery disease.

Further, the report states that one of the major factors hindering the growth of this market is critical ethical challenges with respect to stem cell research. Over the years, there has been a continuous debate over ethical issues related to stem cell therapy. Embryonic stem cell development is continuously debated upon by scientists and policy makers. The use of human embryonic stem cells in research has always concerned decision makers and the scientific fraternity. Some of the issues include the cloning of embryonic stem cells and the destruction of embryos to create cell lines.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Brainstorm Cell Therapeutics
  • Holostem Advanced Therapies
  • Osiris Therapeutics
  • Valeant
  • Vericel
  • AbbVie
  • American CryoStem
  • AM-Pharma
  • Anterogen
  • apceth Biopharma
  • Astellas Pharma
  • Athersys
  • Baxter International
  • Beike Biotechnology
  • BIOTIME
  • bluebird bio
  • Bristol-Myers Squibb
  • Brainxell
  • Caladrius Biosciences
  • Cellular Biomedicine
  • Cellular Dynamics International
  • Cesca Therapeutics
  • CHA Biotech
  • Chugai Pharmaceutical
  • Citospin
  • Corestem
  • Cytori Therapeutics
  • Daiichi Sankyo
  • Fujifilm
  • Gamida Cell
  • Global Stem Cells
  • Grupo Ferrer Internacional
  • GlaxoSmithKline
  • Hemostemix
  • Histocell
  • International Stem Cell
  • Ivy Institute of Stem Cells
  • Japan Regenerative Medicine
  • Kangstem Biotech
  • Kiadis Pharma
  • Laboratorios Salvat
  • MEDIPOST
  • Mesoblast
  • Nuo Therapeutics
  • Opsis Therapeutics
  • Pharmicell
  • Pluristem Therapeutics
  • Promethera Biosciences
  • Q Therapeutics
  • ReNeuron
  • RHEACELL
  • Salus Medical Solutions
  • Sangamo Therapeutics
  • Shire
  • Steminent Biotherapeutics
  • Sumitomo Dainippon Pharma
  • Taiwan Bio Therapeutics
  • Takeda Pharmaceutical
  • Teva Pharmaceutical Industries
  • Thoratec
  • TiGenix
  • Translational Biosciences
  • TWO CELLS
  • U.S. Stem Cell
  • ViaCyte
  • VistaGen Therapeutics.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll